1,25-dihydroxyvitamin d3 ameliorates podocytopenia in rats with adriamycin-induced nephropathy

Internal Medicine

Volumn 49, Issue 24, 2010, Pages 2677-2686

  Zou, Min shu ^a   Yu, Jian ^a   Zhou, Jian hua ^b   Nie, Guo ming ^c   Ding, Dong sheng ^a   Luo, Li man ^a   Xu, Hong tao ^a   He, Wei sun ^a  

^a WUHAN GENERAL HOSPITAL OF GUANGZHOU COMMAND   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c SHANGHAI CHILDREN S HOSPITAL   (China)

Author keywords

Dystroglycan; Integrin; Kidney sclerosis; Podocyte; Vitamin D

Indexed keywords

ALPHA DYSTROGLYCAN; BETA DYSTROGLYCAN; CALCITRIOL; DOXORUBICIN; MESSENGER RNA; NEPHRIN; PODOCIN; VERY LATE ACTIVATION ANTIGEN 3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CELL DENSITY; CELL LOSS; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; GENE EXPRESSION REGULATION; GLOMERULOSCLEROSIS; HISTOPATHOLOGY; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; KIDNEY DISEASE; MALE; NONHUMAN; PODOCYTE; PODOCYTOPENIA; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; PROTEINURIA; RAT; RENAL PROTECTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPRAGUE DAWLEY RAT; TREATMENT DURATION; UPREGULATION; URINALYSIS; WESTERN BLOTTING;

ANIMALS; CALCITRIOL; DOXORUBICIN; GLOMERULONEPHRITIS, MEMBRANOUS; MALE; PODOCYTES; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY;

EID: 78650357952     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.49.4174     Document Type: Article

References (34)

1. Kim YH, Goyal M, Kurnit D, et al. Podocyte depletion and glomerulosclerosis have a direct relationship in the PAN-treated rat. Kidney Int 60: 957-968, 2001.
2. Dalla Vestra M, Masiero A, Roiter AM, Saller A, Crepaldi G, Fioretto P. Is podocyte injury relevant in diabetic nephropathy? Studies in patients with type 2 diabetes. Diabetes 52: 1031-1035, 2003.
3. Mundel P, Shankland SJ. Podocyte biology and response to injury. J Am Soc Nephrol 13: 3005-3015, 2002.
4. Skoberne A, Konieczny A, Schiffer M. Glomerular epithelial cells in the urine: what has to be done to make them worthwhile? Am J Physiol Renal Physiol 296: F230-F241, 2009.
5. Schermer B, Benzing T. Lipid-protein interactions along the slit diaphragm of podocytes. J Am Soc Nephrol 20: 473-478, 2009.
6. Chen CA, Hwang JC, Guh JY, Chang JM, Lai YH, Chen HC. Reduced podocyte expression of alpha3beta1 integrins and podocyte depletion in patients with primary focal segmental glomeruloscle-rosis and chronic PAN-treated rats. J Lab Clin Med 47: 74-82, 2006.
7. Regele HM, Fillipovic E, Langer B, et al. Glomerular expression of dystroglycans is reduced in minimal change nephrosis but not in focal segmental glomerulosclerosis. J Am Soc Nephrol 11: 403-412, 2000.
8. Alborzi P, Patel NA, Peterson C, et al. Paricalcitol reduces albu-minuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. Hypertension 52: 249-255, 2008.
9. Tian J, Liu Y, Williams LA, Zeeuw DD. Potential role of active vitamin D in retarding the progression of chronic kidney disease. Nephrol Dial Transplant 22: 321-328, 2007.
10. Kuhlmann A, Haas CS, Gross ML, et al. 1,25-Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the sub-totally nephrectomized rat. Am J Physiol Renal Physiol 286: F 526-F533, 2004.
11. Shui HA, Ka SM, Lin JC, et al. Fibronectin in blood invokes the development of focal segmental glomerulosclerosis in mouse model. Nephrol Dial Transplant 21: 1794-1802, 2006.
12. Nakamura T, Ushiyama C, Hirokawa K, et al. Effect of cerivasta-tin on proteinuria and urinary podocytes in patients with chronic glomerulonephritis. Nephrol Dial Transplant 17: 798-802, 2002.
13. Calkin AC, Giunti S, Jandeleit-Dahm KA, Allen TJ, Cooper ME, Thomas MC. PPAR-α and -γ agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse. Nephrol Dial Transplant 21: 2399-2405, 2006.
14. Schiffer M, Mundel P, Shaw AS, Bottinger EP. A novel role for the adaptor molecule CD2-associated protein in transforming growth factor-beta-induced apoptosis. J Biol Chem 279: 37004-37012, 2004.
15. Yamauchi K, Takano Y, Kasai A, et al. Screening and identification of subatances that regulate nephrin gene expression using engineered reporter podocytes. Kidney Int 70: 892-900, 2006.
16. Barisoni L, Kriz W, Mundel P, D'Agati V. The dysregulated podo-cyte phenotype: a novel concept in the pathogenesis of collapsing idiopathic focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol 10: 51-61, 1999.
17. Kreidberg JA, Symons JM. Integrins in kidney development, function, and disease. Am J Physiol 279: F233-F242, 2000.
18. Kreidberg JA, Donovan MJ, Goldstein SL, et al. Alpha 3 beta 1 integrin has a crucial role in kidney and lung organogenesis. Development 122: 3537-3547, 1996.
19. Kerjaschki D, Neale TJ. Molecular mechanisms of glomerular injury in rat experimental membranous nephropathy (Heymann nephritis). J Am Soc Nephrol 7: 2518-2526, 1996.
20. Chen HC, Chen CA, Guh JY, Chang JM, Shin SJ, Lai YH. Altering expression of alpha3beta1 integrin on podocytes of human and rats with diabetes. Life Sci 67: 2345-2353, 2000.
21. Kojima K, Matsui K, Nagase M. Protection of alpha(3) integrin-mediated podocyte shape by superoxide dismutase in the puromy-cin aminonucleoside nephrosis rat. Am J Kidney Dis 35: 1175-1185, 2000.
22. Adler S. Characterization of glomerular epithelial cell matrix receptors. Am J Pathol 141: 571-578, 1992.
23. Raats CJ, van den Born J, Bakker MA, et al. Expression of agrin, dystroglycan, and utrophin in normal renal tissue and in experimental glomerulopathies. Am J Pathol 156: 1749-1765, 2000.
24. Wharram BL, Goyal M, Wiggins JE, et al. Podocyte depletion causes glomerulosclerosis: diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor trans-gene. J Am Soc Nephrol 1610: 2941-2952, 2005.
25. Pavenstädt H, Kriz W, Kretzler M. Cell biology of the glomerular podocyte. Physiol Rev 83: 253-307, 2003.
26. Yu D, Petermann A, Kunter U, Rong S, Shankland SJ, Floege J. Urinary podocyte loss is a more specific marker of ongoing glomerular damage than proteinuria. J Am Soc Nephrol 164: 1733-1741, 2005.
27. Dessapt C, Baradez MO, Hayward A, et al. Mechanical forces and TGFβ1 reduce podocyte adhesion through α3β1 integrin down regulation. Nephrol Dial Transplant 19: 1093-1098, 2009.
28. Vogtländer NP, Dijkman H, Bakker MA, Campbell KP, van der Vlag J, Berden JH. Localization of alpha-dystroglycan on the po-docyte: from top to toe. J Histochem Cytochem 5311: 1345-1353, 2005.
29. Pagtalunan ME, Miller PL, Jumping-Eagle S, et al. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 99: 342-348, 1997.
30. Makibayashi K, Tatematsu M, Hirata M, et al. A vitamin D analog ameliorates glomerular injury on rat glomerulonephritis. Am J Pa-thol 158: 1733-1741, 2001.
31. Schwarz U, Amann K, Orth SR, Simonaviciene A, Wessels S, Ritz E. Effect of 1,25 (OH)2 vitamin D3 on glomerulosclerosis in sub-totally nephrectomized rats. Kidney Int 53: 1696-1705, 1998.
32. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 110: 229-238, 2002.
33. Matsui I, Hamano T, Tomida K, et al. Active vitamin D and its analogue, 22-oxacalcitriol, ameliorate puromycin aminonucleoside-induced nephrosis in rats. Nephrol Dial Transplant 24: 2354-2361, 2009.
34. Xiao HQ, Shi W, Liu SX, et al. Podocyte injury is suppressed by 1,25-dihydroxyvitamin D via modulation of transforming growth factor-beta 1/bone morphogenetic protein-7 signalling in puromy-cin aminonucleoside nephropathy rats. Clin Exp Pharmacol Physiol 36: 682-689, 2009.